论文部分内容阅读
作者曾报告鼻咽癌病人血清中存在一种抑制EBV抗原的抑制因子。本文以25例病理学确诊的鼻咽癌病人,20例其他大颈部肿瘤和20个健康人为对象,进一步研究比较了淋巴细胞刺激抑制(LSI)试验与EBV相关抗原的抗体测定在诊断和预后未分化鼻咽癌上的作用。LSI 试验方法:将稀释血清与紫外线灭活的P3HR—1病毒(10~7颗粒/毫升)或从Raji 细胞提取的可溶性EBV 抗原4单位混合,3T℃预孵育1小时,然后取0.1ml 血清抗原混和物和等量的径淋巴细胞刺激试验(LST)证明有细胞免疫反应的健康人周围血淋巴细胞(1×106/毫升)置微量培养板中,于含
The authors have reported that there is an inhibitor of EBV antigen in the serum of patients with nasopharyngeal carcinoma. In this paper, 25 cases of nasopharyngeal carcinoma patients diagnosed pathologically, 20 cases of other large neck tumors and 20 healthy people as the object, further research and comparison of lymphocyte stimulation inhibition (LSI) test and EBV-associated antigen antibody determination in the diagnosis and prognosis Undifferentiated effects on nasopharyngeal carcinoma. LSI test method: Mix diluted serum with UV-inactivated P3HR-1 virus (10-7 particles/ml) or soluble EBV antigen extracted from Raji cells in 4 units, pre-incubate at 3T°C for 1 hour, and then take 0.1 ml of serum antigen Mixtures and equal amounts of lymphocyte stimulation test (LST) demonstrated that healthy human peripheral blood lymphocytes with a cellular immune response (1 x 106/ml) were placed in microplates containing